Francesco Roselli

Francesco Roselli

Auto-generated profile, based on publicly available information

Francesco Roselli

Department of Neurology, Ulm University, Ulm, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Neuron
Verified
Journal Article
Closed access
SSSmita Saxena
Smita Saxena
FRFrancesco Roselli
Francesco Roselli
KSKatyayani Singh
Katyayani Singh
KLKerstin Leptien
Kerstin Leptien
JJJean-Pierre Julien
Jean-Pierre Julien
PCPico Caroni
Pico Caroni

30 November 2005 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
FRF. Roselli
F. Roselli
MTM. Tirard
M. Tirard
JLJIE LU
JIE LU
PHP. Hutzler
P. Hutzler
PLP. Lamberti
P. Lamberti
OAO. F. X. Almeida
O. F. X. Almeida
Amyloid-β (Aβ) has been implicated in memory loss and disruption of synaptic plasticity observed in early-stage Alzheimer's disease. Recently, it has been shown that soluble Aβ oligomers target synapses in cultured rat hippocampal neurons, suggesting a direct role of Aβ in the regulation of synaptic structure and function. Postsynaptic density-95 (PSD-95) is a postsynaptic scaffolding protein that plays a critical role in synaptic plasticity and the stabilization of AMPA (AMPARs) and NMDA (NMDARs) receptors at synapses. Here, we show that exposure of cultured cortical neurons to soluble oligomers of Aβ1-40reduces PSD-95 protein levels in a dose- and time-dependent manner and that the Aβ11-40-dependent decrease in PSD-95 requires NMDAR activity. We also show that the decrease in PSD-95 requires cyclin-dependent kinase 5 activity and involves the proteasome pathway. Immunostaining analysis of cortical cultured neurons revealed that Aβ treatment induces concomitant decreases in PSD-95 at synapses and in the surface expression of the AMPAR glutamate receptor subunit 2. Together, these data suggest a novel pathway by which Aβ triggers synaptic dysfunction, namely, by altering the molecular composition of glutamatergic synapses.

17 December 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ALA. C. Ludolph
A. C. Ludolph
JDJohannes Dorst
Johannes Dorst
JDJens Dreyhaupt
Jens Dreyhaupt
JWJochen H. Weishaupt
Jochen H. Weishaupt
JKJan Kassubek
Jan Kassubek
FGfor the LIPCAL‐ALS Study Group
for the LIPCAL‐ALS Study Group

27 March 2018 in eLife
Verified
Journal Article
Open access
MMMaría de Lourdes Martínez-Silva
María de Lourdes Martínez-Silva
RIRebecca D Imhoff-Manuel
Rebecca D Imhoff-Manuel
ASAarti Sharma
Aarti Sharma
CHCj Heckman
Cj Heckman
NSNeil A Shneider
Neil A Shneider
MMMarin Manuel
Marin Manuel
Hyperexcitability has been suggested to contribute to motoneuron degeneration in amyotrophic lateral sclerosis (ALS). If this is so, and given that the physiological type of a motor unit determines the relative susceptibility of its motoneuron in ALS, then one would expect the most vulnerable motoneurons to display the strongest hyperexcitability prior to their degeneration, whereas the less vulnerable should display a moderate hyperexcitability, if any. We tested this hypothesis in vivo in two unrelated ALS mouse models by correlating the electrical properties of motoneurons with their physiological types, identified based on their motor unit contractile properties. We found that, far from being hyperexcitable, the most vulnerable motoneurons become unable to fire repetitively despite the fact that their neuromuscular junctions were still functional. Disease markers confirm that this loss of function is an early sign of degeneration. Our results indicate that intrinsic hyperexcitability is unlikely to be the cause of motoneuron degeneration.

6 June 2018 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
Najwa Ouali AlamiNajwa Ouali Alami
Najwa Ouali Alami
CSChristine Schurr
Christine Schurr
FHFlorian Olde Heuvel
Florian Olde Heuvel
LTLinyun Tang
Linyun Tang
QLQian Li
Qian Li
BBBernd Baumann
Bernd Baumann
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 March 2002 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
GDGiovanni Defazio
Giovanni Defazio
GAGiovanni Abbruzzese
Giovanni Abbruzzese
PGPaolo Girlanda
Paolo Girlanda
LVLAURA VACCA
LAURA VACCA
ACAntonio Currà
Antonio Currà
ABAlfredo Berardelli
Alfredo Berardelli
Research from JAMA Neurology — Botulinum Toxin A Treatment for Primary Hemifacial Spasm — A 10-Year Multicenter Study